The protease inhibitor atazanavir [Reyataz; Bristol-Myers Squibb] has been approved in the EU

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1430, 2004-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bristol-Myers Squibb has announced that it will no longer make or sell the antidepressant Serzone

By  

Reactions Weekly, Vol. 1, Iss. 1007, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Health Canada has granted a notice of compliance for Bristol-Myers Squibb's dasatinib [Sprycel] for use in patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Bristol-Myers Squibb has issued a `Dear Health Care Provider' letter advising of a change in the pregnancy category for Sustiva [efavirenz]

By  

Reactions Weekly, Vol. 1, Iss. 1056, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

By Mateo Ma Gracia   Gutierrez Ma del Mar   Vidal Francesc   Domingo Pere  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite

Roche's bevacizumab [Avastin] has been approved as a first-line treatment for advanced renal cell cancer in the EU

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite